 Monopar Therapeutics Inc. MNPR Chicago, IL and NorthStar Medical Radioisotopes, LLC Beloit, WI announced today that a provisional patent application entitled Precision Radioimmunotherapeutic Targeting of the Urokinase Plasminogen Activator Receptor uPAR for Treatment of Severe COVID-19 Disease has been filed with the U.S. Patent and Trademark Office USPTO. This application covers novel compositions and uses of cytotoxic radioisotopes attached to antibodies that bind to uPAR, thereby creating precision targeted radiotherapeutics uPRITs for the treatment of severe COVID-19 and other respiratory diseases. Advanced COVID-19 patients frequently develop severe, life-threatening, pulmonary inflammation as a result of a viral induced cytokine storm. 